All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Long-term results from a phase Ib/II study of magrolimab plus rituximab in R/R iNHL
By Ella Dixon
|
The 3-year results from a multicenter, phase Ib/II trial (NCT02953509), which investigated magrolimab combined with rituximab (M+R) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), were published in Blood Advances by Mehta et al.1 A total of 46 patients with R/R B-cell NHL were enrolled in phase Ib and received a priming dose of 1 mg/kg magrolimab followed by magrolimab maintenance doses of 10, 20, 30, or 45 mg/kg. In phase II, based on the safety data from phase Ib, maintenance doses of 30 and 45 mg/kg magrolimab combined with 375 mg/m2 rituximab were explored. The primary endpoints included the incidence and severity of treatment-emergent adverse events (TEAEs) and objective response rate (ORR) of M+R combination.1 |
| Key learnings: |
|
At least one TEAE and treatment-related TEAE were reported in 100% and 95.7% of patients, respectively. Infusion-related reaction (60.9%), headache (52.2%), and fatigue (45.7%) were the most common any grade TEAEs. The combination of M+R was well tolerated long term, with no new TEAEs identified during the follow-up period and no treatment-related deaths. |
|
The M+R combination was associated with an ORR of 52.2%, with 30.4% of patients achieving a complete response. Among the responders, the median time to response was 1.8 months and the median duration of response was 15.9 months, indicating durable clinical benefit. |
|
Responses with M+R were comparable across patient subgroups regardless of progression of disease ≤24 months or prior lines of therapy, suggesting its applicability in heavily pre-treated populations. |
|
Median progression-free survival was 7.4 months and the median overall survival was not reached. |
|
The results highlight the potential of M+R in iNHL, particularly for patients with limited treatment options due to refractory disease. Future studies should consider investigating M+R with emerging immunotherapies, such as CAR T-cell therapy or bispecific T-cell engagers, to potentially improve patient outcomes without adding significant toxicity. |
- Mehta A, Popplewell L, Collins GP, et al. Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: Phase 1/2 trial 3-year follow-up. Blood Adv. Online ahead of print. DOI: 10.1182/bloodadvances.2024013277
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
13 votes - 29 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox